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Abstract 
The chromatin structure of the mammalian genome must facilitate both precisely-controlled DNA 
replication together with tightly-regulated gene transcription. This necessarily involves complex 
mechanisms and processes which remain poorly understood. It has long been recognised that the 
epigenetic landscape becomes established during embryonic development and acts to specify and 
determine cell fate. In addition, the chromatin structure is highly dynamic and allows for both 
cellular reprogramming and homeostatic modulation of cell function. In this respect, the functions of 
epigenetic “erasers”, which act to remove covalently-linked epigenetic modifications from DNA and 
histones are critical. The enzymatic activities of the TET and JmjC protein families have been 
identified as demethylases which act to remove methyl groups from DNA and histones, respectively. 
Further, they are characterised as members of the Fe(II)- and 2-oxoglutarate-dependent dioxygenase 
superfamily. This provides the intriguing possibility that their enzymatic activities may be modulated 
by cellular metabolism, oxygen availability and redox-based mechanisms, all of which are likely to 
display dynamic cell- and tissue-specific patterns of flux.  Here we discuss the current evidence for 
such [O2]- and redox-dependent regulation of the TET and Jmjc demethylases and the potential 
physiological and pathophysiological functional consequences of such regulation.  
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Introduction 
The DNA comprising the genome of a single human (diploid) cell comprises more than 6 billion base 
pairs which, if stretched end to end, would extend to about 2 metres. That this becomes packaged 
into a nucleus of approximately 6 m in diameter, in such a way that allows its code to be used to 
control every function of the cell, seems truly remarkable.  Eukaryotic genomic DNA is hierarchically 
compacted into chromatin. It is wound around octamers of histone proteins (consisting of 2 copies 
of each of the core histones: H2A,H2B H3 and H4) to form a linear nucleosomal array which is then 
further folded and organised by association with linker histones to generate higher-order chromatin 
structures [1].  Eukaryotic  DNA is compartmentalised into the histologically-distinct forms of highly-
condensed (inaccessible, “repressive”) heterochromatin and the more loosely-packed (accessible, 
“active”) euchromatin [2]. As many as five structural sub-types of chromatin have been identified in 
Drosophila cells (two types of “active” chromatin, and 3 types of “repressive” chromatin) [3].  It is 
also clear that both heterochromatin and euchromatin can be further subdivided and characterised 
in mammalian cells [4].  It is now recognised that the structure of chromatin is highly dynamic [5] 
and that this plasticity in the degree of chromatin condensation is essential to facilitate the 
regulation of cellular processes which necessitate access of catalytic proteins to DNA, such as DNA 
replication, transcription and DNA repair.  
The term “epigenetic” roughly summarizes all changes at the nuclear and mitochondrial DNA (nDNA 
and mtDNA) or RNA level, which alter their structure or conformation, but not their primary 
sequence, and affect gene expression and hence cellular function[6]. Thus, to a large extent, the 
study of epigenetics involves understanding the mechanisms involved in regulating the remodelling 
of chromatin structure to facilitate accessibility of specific gene loci to their cognate transcription 
factors. Epigenetic regulatory mechanisms are therefore fundamental to the acquisition of cell fate 
during embryonic development and the mediation of physiological cellular homeostasis. Further, the 
dysregulation of epigenetic processes correlate with, and may be causal in, the development and 
progression of disease, and most notably cancer [7].   
Epigenetic Modifications affecting Chromatin Structure 
The degree of compaction and hence accessibility of specific genetic loci can be regulated by both 
the replacement of the canonical core histones (H2A, H2B H3 and H4) with histone variants 
(reviewed in [8]) and ATP-dependent chromatin remodelling complexes (reviewed in [9]). In 
addition, reversible covalent modifications of the genomic DNA itself and of the N-terminal tails of 
the histone proteins are critical processes involved in the regulation of chromatin structure. In the 
case of the DNA, the most prevalent covalent modification is methylation of the C5-position of 
cytosine (5-methylcytosine; 5mC), predominantly at CpG dinucleotides [10].  Within the human 
genome, about 70% of CpG sites are methylated, but this equates to only about 5% of all cytosine 
residues [11]. Thus, CpG dinucleotides occur relatively infrequently and are typically concentrated in 
short CpG-rich DNA tracts termed “CpG islands”. Most human gene promoters (50–70%) are 
embedded within such CpG islands and their methylation is normally associated with transcriptional 
repression [10]. Consequently, analyses of differentially-methylated DNA loci have shown the co-
localisation of hypomethylated regions with promoters and enhancers of actively transcribed, tissue-
specific and developmental stage-specific genes [12, 13].  
By contrast to DNA epigenetic modification, there is an enormous complexity of possible post-
translational modifications of histone proteins. In addition to methylation, different histone proteins 
can be subject to acetylation, phosphorylation, ubiquitination, GlcNAcylation, citrullination, 
hydroxylation and SUMOylation [14], which each elicit specific (both positive and negative) effects 
upon chromatin compaction and structure and hence gene function. There is also far greater 
complexity with the regard to both the location and degree of each specific modification. All 
histones can theoretically be methylated at arginine and lysine residues, and an ever-increasing 
number of residues have been empirically shown to be targeted [15-19].  However, some residues 
are more frequently methylated, such as Lysine (K)-4, -9, -27, -36 and -79 of histone H3, and K-20 of 
histone H4 (reviewed in [20]). In mammalian cells, di-methylation is most common (an estimated 40-
80% of all histones are di-methylated at H3K9, H3K27, H3K36 and H4K20), while mono- and tri-
methylation modifications of these residues are less abundant (affecting approximately 20% of 
histones) [21, 22]. The structures and functions of the epigenetic modifiers which act to add or 
remove these modifications are becoming increasingly well characterised [23].  However, the 
mechanisms that underlie the enormous complexity of their dynamic regulation of function in 
(patho)-physiological cellular processes are not understood.  
DNA and Histone Methylation; Epigenetic Regulation by Members of the 2-oxoglutarate-
dependent Dioxygenase Superfamily 
The chromosomal patterns of both DNA and histone methylation are maintained by the opposing 
actions of enzymatic methylase and demethylase systems, termed epigenetic “writers” and 
“erasers” respectively [24]. In the case of DNA, methylation at CpG dinucleotides is achieved by DNA 
methyltransferases (DNMTs) of which there are 3 in mammals, with proven and essential 
methyltransferase activity; DNMT1, DNMT3a and DNMT3b [25]. These catalyse the transfer of a 
methyl group from the universal methyl donor, S-adenosyl-L-methionine (SAM), to the C5 position of 
cytosine. DNMT1 acts solely upon hemimethylated DNA and therefore acts to maintain methylation 
status after DNA replication, while DNMT3a and DNMT3b are additionally  involved in de novo DNA 
methylation [25]. Similarly, SAM is utilised in the methylation of histone proteins by three distinct 
histone methyltransferase (HMT) enzymatic systems: SET domain lysine methyltransferases, non-SET 
domain lysine methyltransferases and arginine methyltransferases (reviewed in [26]). Although 
methylation of the histone tails does not alter the charge of the proteins, it increases their 
hydrophobicity and hence can alter the affinity of specific proteins such as transcription factors for 
their cognate DNA binding sites [27].   
It is, perhaps, noteworthy that the activities of both the DNMTs and the HMTs are dependent upon 
the intracellular levels of SAM, which fluctuate based upon the cellular nutrient availability [28].  This 
therefore potentially provides a sensory-mechanistic link between metabolism, energy homeostasis 
and the regulation of gene expression by methylation of histones and DNA.  
For many years, the methylation of both DNA and histone proteins were thought to be irreversible 
modifications, which would be lost from the chromatin only by “passive” mechanisms during DNA 
replication. However, more recently, active demethylation enzymatic processes have been 
characterised, which are predominantly catalysed by members of the superfamily of Fe(II)-, and 2-
oxoglutarate-dependent dioxygenases (2-OGDDs) [29]. 2-OGDDs are widely distributed throughout 
the animal and plant kingdoms, and more than 60 such enzymes have been identified in humans 
alone [30]. These are involved in diverse biochemical roles associated with fatty acid metabolism, 
carnitine biosynthesis and phytanic acid catabolism [31]. They catalyse a variety of oxidative 
transformations, of which the most studied and well-established (and that which is relevant here) is 
hydroxylation of a respective substrate (reviewed in [32]). The absolute requirement of these 
enzymes for 2-oxoglutarate (2-OG) may (as in the case of the methylases) provide a link between the 
cellular metabolic status and their enzymatic activity. In addition, their requirement for molecular 
oxygen might suggest potential roles as O2 sensors, while the necessity for Fe(II), (and inhibition by 
Fe(III)), may additionally suggest potential regulation by cellular-redox status and/or redox-signalling 
mechanisms. These intriguing characteristics may therefore facilitate roles of these demethylases in 
the epigenetic-determination of specific patterns of gene expression, both during normal cellular 
development and in the physiological homeostatic responses to cellular stresses. In addition, they 
may provide mechanistic insights into the epigenetic dysregulation observed during disease. 
DNA Demethylation by Ten-Eleven Translocation Enzymes (TETs) 
The 5mC modification was found not to be a stable, irreversible modification of DNA, when the 
significant and unexpected observation was made that the ten eleven translocation protein 1 (TET1) 
was able to catalyse its conversion to 5-hydroxymethyl cytosine (5hmC) [33]. TET1 had originally 
been cloned and characterised as an acute myeloid leukaemia-associated protein of unknown 
physiological function, which translocated to generate a fusion partner with mixed-lineage 
leukaemia (MLL) [34, 35].  Its translocation from chromosome ten to chromosome eleven 
determined its nomenclature. Based on sequence homology, two additional paralogues were 
identified in human and mouse (TET2 and TET3) [34]. Sequence homology between TET proteins and 
the trypanosome proteins, JBP1 and JBP2, which are 2-OGDD enzymes that were believed to oxidise 
the 5-methyl group of thymine, led to the proposal of the involvement of TET proteins in epigenetic 
modification [33]. Subsequently, the occurrence of TET-dependent 5hmC within the mammalian 
genome confirmed this. Thus, it is now recognised that TET1, TET2 and TET3 all catalyse successive 
oxidations of 5mC to 5hmC, 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) [36, 37]. These 
oxidised cytosine modifications can subsequently be lost upon DNA replication.  Alternatively, active 
demethylation can be achieved by thymine DNA glycosylase (TDG)-dependent removal of 5fC and 
5caC, coupled with base excision repair (reviewed in[38], see Figure 1A).  
In addition to their presence as intermediates in the demethylation process, these oxidised forms 
are also recognised as relatively stable epigenetic modifications in the genomic DNA of both dividing 
and non-dividing cells [39, 40], with specific regulatory functions that are increasingly being 
elucidated [41, 42]. Oxidation products of 5mC have been identified in all mammalian tissues 
examined, albeit at low and variable levels. Thus, while 5mC is found in all tissues to correspond to 
approximately 5% of all cytosines, 5hmC has been reported to be present at approximately 0.5% of 
all cytosines in the CNS [43], 0.08% in embryonic stem cells (ESCs) [44] and 0.03%-0.06% in the 
spleen and testes [43]. The products of further oxidation have been less studied, but current 
estimates suggest 5fC and 5caC to be present at approximately 10-fold to 100-fold lower levels than 
5hmC (reviewed in [43]). In broad agreement with this, kinetic studies of the TET catalytic activity 
indicate that the rate of 5hmC and 5fC oxidation is significantly reduced (approximately 5.6 fold and 
10.2 fold respectively), compared to the initial rate of 5mC oxidation [37, 45], indicative of a lower 
substrate preference for the more oxidised cytosine modifications.  
In addition to their roles in 5mC oxidation and turnover, TET proteins have also been shown to 
catalyse the oxidation of thymine bases in DNA to form 5-hydroxymethyluracil (5hmU) in ESCs, albeit 
in very low amounts [46]. The epigenetic significance of this modification, however, remains to be 
explored.  
The three mammalian TET proteins have broadly similar structures. They all contain a C-terminal, 
core catalytic domain comprising a double-stranded -helix (DSBH) adjacent to a cysteine-rich 
domain [47] (Figure 2). This catalytic domain alone has been shown to be able to localise to the 
nucleus and oxidise 5mC [33, 48, 49]. The nuclear localisation of all 3 native TET proteins has been 
demonstrated, although there is also evidence of their translocation to the cytoplasm under some 
cellular conditions [50]. TET1 and TET3 also contain an N-terminal, DNA-targeting, CXXC domain [51]. 
By contrast, the putative CXXC domain of TET2 is encoded by a distinct gene, termed Idax, that has 
become separated from Tet2 by a genomic inversion during evolution [47, 52]. The differential 
tissue- and developmental stage-specific patterns of the TET proteins, together with their 
physiological and pathophysiological functions, are increasingly becoming established (Table 1). 
Splice variants have also been identified for all three paralogues, including, in the case of TET1 and 
TET3, variants which lack the CXXC domain, and serve distinct functional roles [53-55]. 
Histone Demethylation by the Jumonji Family of 2-OGDD Proteins 
Histone methylation, like DNA methylation, was thought to be a stable, covalent modification, until 
the discovery of enzymatic systems which can remove it. Two classes of enzymes, the lysine-specific 
demethylase (LSD) family and members of the Jumonji C (JmjC) family, are now recognised to effect 
histone demethylation by distinct mechanisms. The LSD family consist of FAD-dependent amine 
oxidases, which can remove both mono- and di-methyl histone lysine marks, but cannot 
demethylate tri-methyl lysine residues. (For a recent review of the LSD family, see [56]). The JmjC 
family are grouped on the basis of the presence of homology to a catalytic “jumonji” domain. 
Jumonji is a mouse mutation, named after the Japanese word for cross, which was identified in a 
gene trap screen and exhibited an abnormal, cross-shaped neural groove morphology [57]. The JmjC 
domain-containing proteins, like the TETs, are members of the 2-OGDD superfamily and were 
predicted and subsequently demonstrated to hydroxylate mono-, di- and tri-methylated lysine and 
arginine residues in N-terminal histone tails (reviewed in [20];  Figure 1B). There are currently over 
30 proteins identified in humans to belong to the JmjC group and most (but not all) of these have 
been associated with histone demethylation (reviewed in [58]). They can be further classified into 
subfamilies, which typically may share substrate specificity, dependent upon the presence of other 
domains, including the TUDOR, CXXC, PHD, FBOX, ARID, LRR and JmjN domains (reviewed in[59]; 
Table 2). As is the case for the TET enzymes, specific physiological and pathophysiological roles are 
increasingly been identified for different JmjC demethylases, notably in development and certain 
cancers (reviewed in [60, 61]; Table 2).  
HIF-PHD and FIH; Prototype Oxygen sensors? 
Molecular oxygen (O2) is an obligate substrate for all 2-OGDDs, which raises the intriguing possibility 
that these chromatin erasers may act as primary O2 sensors in development, homeostasis and/or 
disease. The most highly studied members of the 2-OGDD superfamily, which are established to play 
a role in O2-sensing, are the three closely-related hypoxia-inducible factor-1 prolyl hydroxylases (HIF-
PHD1-3) [62]. These act to regulate the stability, and hence activity, of the hypoxia- (and other 
stress-) inducible transcription factor, HIF. Under well-oxygenated conditions, HIF-PHDs act to 
hydroxylate specific, conserved proline residues within the HIF subunit (of which there are three 
homologues in higher metazoans). This creates a structural change in the protein that renders it 
subject to proteasomal degradation via binding to the von Hippel-Lindau (VHL) protein (a 
component of the ubiquitin ligase complex) [62]. Another 2-OGDD enzyme, termed factor-inhibiting-
HIF (FIH), similarly utilises O2 to hydroxylate a conserved asparagine residue within the HIF subunit 
[63]. This results in a steric inhibition of the recruitment of the transcriptional coactivators, p300 and 
CBP, further inhibiting the activity of HIF under well-oxygenated conditions. Under hypoxia, the 
activities of both PHDs and FIH are compromised, allowing the HIF-dependent transcriptional 
activation of a plethora of genes involved in processes involved in the homeostatic responses to 
hypoxia, including metabolism, angiogenesis and erythropoiesis [62].  
However, for PHDs and FIH to be considered true oxygen sensors, their KM values for oxygen (the 
concentrations of oxygen that support a half-maximal initial catalytic rate) must be such to allow for 
the modulation of their activities within ranges typically found in tissues (10-30M). The studies 
performed to determine the KMs for O2 of these enzymes have yielded differing results (Table 3). 
Currently, the consensus is that while PHDs are likely to be bona-fide direct O2 sensors, at least in 
some cell and tissue types, the observed (low) KM values of FIH preclude it from being considered a 
true O2 sensor [62, 64].  
Evidence for Regulation of TETs by [O2] 
It is an intriguing possibility that, like PHDs, the epigenetic modifying members of the 2-OGDD 
superfamily might also act, in some cases, as oxygen sensors. Individual TET proteins are increasingly 
being shown to play specific functional roles in embryonic development, both in the maintenance of 
pluripotency in ESCs, and in the acquisition of cellular fate [48, 65, 66]. In addition, the dysregulation 
of TETs has been associated with, (and in some cases has been suggested to be causal in), the 
development and progression of some pathologies, most notably cancer [67]. In both these 
physiological and pathological settings, the availability of molecular oxygen is known to be a critical 
determining factor.  
The KM values for O2 of the purified catalytic domains of both TET1 and TET 2 have been 
investigated, and were found to be relatively equivalent, and of the order of 30M [68]. This is 
considerably lower than values reported for the HIF-PHDs (90-250M [69, 70]), and suggests that 
the TETs would retain significant activity under relatively hypoxic conditions. However, in a separate 
study, the effects of varying O2 concentrations upon the activities of purified, recombinant TET1 and 
TET2 were determined. Significant reductions (45% and 52% for TET1 and TET2 respectively) were 
observed at 0.5% O2 [71], suggesting that the activities of these enzymes could be modified by 
available [O2], in some cellular environments. The reason for the discrepancy in these results is not 
clear, but may reflect the use of truncated, catalytic domains, compared to full-length proteins. The 
KM of TET3 for O2 has not been determined to date.    
 A reduction in TET activity and 5hmC levels  is a hallmark of many tumours [72] and yet, perhaps 
significantly,  mutations in the TET enzymes themselves have often not been identified [72]. This 
might reflect the activities of TETs becoming compromised in the more hypoxic, tumorigenic 
environment. Consistent with this, several human and mouse cancer cells, which were cultured 
under graded hypoxic conditions that were physiologically relevant to the tumour environment 
(down to 0.5% O2), exhibited a dose- and time-dependent decrease in global 5hmC levels [71]. It 
should, however, be noted that the precise intracellular concentrations of O2, achieved in such 
experiments, are difficult to assess and are likely to fluctuate due to cellular O2 consumption and the 
rate of diffusion of O2 through the media [73, 74]. These limitations similarly apply to the 
interpretation of other cell culture-based experiments described below.  In vivo, the gene-expression 
patterns of tumours are known to reflect the hypoxic level of their environment [75] and have been 
used to assign them to hypoxic, normal or intermediate groups. Analyses of the methylation status 
of tumours demonstrated the hyper-(5mC)-methylated cluster to be predominantly associated with 
the more hypoxic tumours, whereas the low-methylated cluster were enriched for normoxic 
tumours [71]. The causal significance of [O2] with regard to the methylation status of tumour tissue 
in vivo was also demonstrated in this study. Thus, increased hypoxia in mouse breast tumours was 
shown to increase hypermethylation, while restoration of oxygenation to the tumour abrogated this 
effect. The inhibition of TET activity may, at least in part, account for these observations.  
The importance of TETs in ESC differentiation and mammalian development are increasingly being 
demonstrated [48, 65, 66, 76-85]. Graded levels of O2 are known to exist within the developing 
mammalian embryo [86-88], and it is intriguing to speculate that the differential activities of TETs, 
dependent upon their distinct microenvironments, might (in part) be a determinant of cellular fate 
during differentiation. We recently investigated the effects of the available [O2], upon the activities 
of each of the three TET enzymes (as assessed by levels of 5hmC), when overexpressed in HEK-293T 
cells [44]. Our data demonstrated distinct patterns of inhibition of the three paralogues by [O2] over 
a range (0.5-5%) that is physiologically relevant within the developing embryo [88, 89]. Thus, the 
activity of TET1 was unaltered in cells cultured at 5%, compared to atmospheric (~21%) O2, but was 
significantly reduced upon culture at 3% O2 and below. By contrast, the activity of TET2 remained 
unchanged at 3%, compared to atmospheric, O2 (and was little inhibited at [O2] as low as 0.5%). 
Surprisingly, we also found that the activity of TET3 was increased at 3%, relative to atmospheric O2, 
but decreased again at levels below that [44]. We hypothesise that hypoxic culture conditions might 
result in changes in levels of TCA metabolites, which are known to affect the activity of 2-OGDDs. 
Accordingly, the levels of fumarate and succinate (metabolites known to inhibit TET proteins due to 
competitive steric inhibition of 2-OG) were found to be significantly decreased in HEK-293T cells 
cultured at 3%, compared to atmospheric, O2.  
The observations above therefore suggest that the activities of the TET proteins might be 
differentially-regulated by graded levels of O2, and by levels of TCA metabolites, which themselves 
might be dependent upon O2 availability, probably in a cell-type-specific manner. It can further be 
envisaged how the differential activities of the TET proteins might combine to generate distinct 
patterns of 5hmC levels within the developing embryo, dependent upon the (spatio-specific) [O2] 
(Figure 3). Intriguingly, we also evidenced a transient burst of increased 5hmC during early mouse 
ESC differentiation that was both dependent upon TET1 (specifically), and inhibited by low (1%) [O2]. 
The precise significance of these findings in regard to the acquisition of cell fate during development 
remains to be determined. However, they demonstrate the potential of the differential regulation of 
TET activities to effect the [O2]-dependent establishment of distinct epigenetic cellular programmes 
during development.  
In addition to the ability of [O2] to regulate TET activity, multiple studies have demonstrated the 
transcriptional expression of TET enzymes to be dependent upon the cellular O2 availability. Thus, 
increases in TET1/2 and 3 have all been reported in various cell types under hypoxic conditions [71, 
90-94] which, in some cases, have been demonstrated to be dependent upon HIF1 [71, 91, 93].  As in 
the case of TET activity, the levels of expression of the different TET proteins show distinct patterns 
of sensitivity to different levels of hypoxia [93]. In addition, the expression of TET2 has also been 
reported to be inhibited in the glioblastoma cells line, A172, under more hypoxic cell culture 
conditions (by contrast to TET1 and TET3 whose expression was significantly increased) [94]. Thus, 
[O2] may act differentially upon the TET proteins and in a cell-type specific manner to regulate their 
expression.  
There is also evidence that the TET proteins participate functionally in the cellular hypoxic response, 
further strengthening the potential relationship between TET proteins and O2-sensing mechanisms. 
For instance, in neuroblastoma cells, both TET1 function and increased levels of 5hmC were found to 
be causal in regulating the hypoxia-induced transcriptional program [95]. A subset of genomic 
locations which became enriched for 5hmC in hypoxia were found to be at, or near, HIF-1 binding 
sites, and to facilitate HIF binding. The functional involvement of TETs in a novel pathway by which 
hypoxia promotes tumour malignancy has also been reported. Thus, in primary breast cancer cells, 
hypoxia induced the HIF1-mediated expression of TET1 and TET3, together with a global increase in 
5hmC. Further, TET1 and TET3 were shown to act co-ordinately to activate the TNF-p38-MAPK 
signalling pathway and the acquisition of tumorigenic characteristics, via direct co-binding to the 
TNF gene promoter [96].  
Intriguingly, several studies have suggested that the transcriptional expression of the TETs 
themselves may further be regulated by hypoxia-induced changes in 5hmC (and thus potentially 
5mC). Thus, the methylation status of both the Tet1 and Tet2 gene promoters in retinal pigment 
epithelial cells were found to become hypomethylated under conditions of chemically-induced 
hypoxia [90]. In addition, as stated above, we observed a transitory burst of 5hmC generation during 
early-differentiating ESCs that was dependent upon TET1 and was inhibited under low (1%) O2 [44]. 
Strikingly, the major genomic target which became enriched for 5hmC in this system was shown to 
be Tet3. Given the association between TET3 expression and neural differentiation and function that 
is increasingly becoming elucidated [66, 97, 98], these observations may give further clues as to how 
gradients of [O2] (known to be present in the early embryo) may act to determine cell fate, via 
regulation of TET functions (See Figure 4 for associations between [O2] and TET function).  
Regulation of JmjCs by Oxygen Availability 
As in the case of the TET enzymes, the dysregulation of specific JmjC proteins (with known 
demethylase activity) has been shown to be associated with both developmental impairment and 
tumorigenesis; processes known to be dependent upon molecular oxygen availability (reviewed in 
[61, 99], see also Table 2). Moreover, many studies have demonstrated that exposure to hypoxia can 
alter the methylation status of histones and the epigenetic landscape in cultured cells (reviewed in 
[100]). Consistent with hypoxia acting to inhibit JmjC activity, increased H3K4me3, H3K9me2/me3 
and H3K36me3 levels have all been reported under low [O2] conditions [101-103]. In one case, this 
was attributed to the specific inhibition of KDM5A (JARID1A) [103]. Some in vitro kinetic studies have 
also demonstrated the dependence of the activities of specific JmjC members upon [O2]. For 
example, the activity of recombinant, (pseudogene-encoded) KDM4E was shown to display a near-
linear, graded response to O2, over a physiologically-relevant concentration (0.5 to 20%) range. This 
study further demonstrated that the enzymatic activity was very dependent upon the methylation 
status of the substrate, since enhanced activity was observed upon a higher-methylated substrate 
[104].  More recently, the activity of KDM4A (both when expressed in cells, and as purified protein) 
was shown to demonstrate a graded reduction in response to depleting O2 concentrations [105]. 
Also, as we observed for the TET activities, there is some evidence that JmjC enzymes might be 
differentially regulated by levels of O2. Thus, when overexpressed in HeLa cells, KDM3A (JMJD1A) 
activity was maintained under 0.2% O2, while that of KDM4B (JMJD2B) was attenuated [106].  
While the KM values for the JmjC proteins have proven technically challenging to evaluate, some 
estimates have been made (Table 3). These data also indicate the differential sensitivity of JmjCs 
towards reduced O2 levels, and suggest the potential for some, but likely not all, to be sensitive to 
physiological changes in [O2]. This differential regulation of activity by oxygen may be of particular 
functional significance during embryonic development. Genes that are poised for activation (as 
required during subsequent differentiation) are marked with both positive (H3K4me3) and 
repressive (H3K27me3) histone methylation marks.  This bivalent state is both established and 
resolved by Polycomb and Trithorax group complexes, which can recruit JmjCs, as appropriate, to 
remove the activating or repressive mark [107]. Clearly, the differential sensitivities of these 
activities to O2 could act to determine which sets of genes were activated or repressed, dependent 
upon their spatial position and local O2 microenvironment.  
Another mechanism whereby hypoxia has been shown to regulate the activities of the JmjC proteins 
in mammalian cells is via induction of the enzymatic reduction of 2-OG to generate the 
“oncometabolite” D-2-hydroxyglutarate (D-2HG). D2HG is a competitive inhibitor of 2-OGDDs, 
including JmjCs, and has been shown in various cell types to act to increase methylation marks, 
including H3K9me3, under hypoxic conditions [108].   
In addition, as was found to be the case for DNA methylation, the relationship between hypoxia, 
JmjC function and histone methylation is complex. Many JmjC proteins are known to be direct 
transcriptional targets of HIF and therefore their expression levels increase under more hypoxic 
conditions. These include KDM3A, KDM4B, KDM4C, KDM5B, and KDM5C [106, 109-113].   Moreover, 
the expression of some other JmjC proteins have also been shown to increase in hypoxia, although 
they have not been identified as direct HIF targets, suggesting the contribution of additional 
mechanism(s) [58, 114, 115]. Again, as was found to be the case for the TETs, there is evidence for 
the involvement of JmjCs in the functional cellular response to hypoxia. Thus, under hypoxia, the 
increased expression of KDM3A promotes its binding at HRE sites within the regulatory regions of 
the HIF target genes. This then promotes demethylation of the (repressive) H3K9me2/me3 mark and 
induction of gene expression [116]. A direct interaction between HIF1 and (increased levels of) 
KDM4C has also been observed in hypoxia. In this case it has been proposed that HIF1 is 
responsible for guiding KDM4C to its target promoters, again to enhance the demethylation of the 
H3K9me2/me3 mark and upregulate gene expression [117]. This has been demonstrated to be of 
potential functional significance in tumorigenesis, since ablation of KDM4C in mice acted to inhibit 
breast tumour growth and lung metastasis. The composite relationships between hypoxia, JmjC 
activity, expression and target specificity will therefore underlie distinct cell type- and locus-specific 
changes in histone methylation patterns in response to hypoxia.  
Regulation of 2-OGDD Proteins by Redox-Dependent Mechanisms 
The catalytic domain of 2-OGDDs is remarkably well-conserved across proteins of diverse functions 
[118].  All comprise a core structural motif consisting of  eight -strands arranged in a “jelly roll” or 
double-stranded -helix, which is surrounded by -helices[119]. Within this jelly roll a non-heme, 
ferrous (Fe2+) iron is co-ordinated by a triad of two histidines and aspartate/glutamate. The 
remaining three co-ordination sites of the iron are only loosely occupied by labile water molecules 
[119]. This relatively low affinity of 2-OGDDs for iron renders the activities of the enzymes 
potentially susceptible to changes in cellular iron concentrations.  In addition, it also renders the 
ferrous ion itself vulnerable to oxidation to the ferric (Fe3+) state, which is known to be inhibitory to 
2-OGDD activity [120]. However, it should be noted that despite this co-ordination chemistry 
predicting a labile arrangement, the apparent KM values of, for instance, the HIF-PHDs for Fe
2+ are 
surprisingly low (Table 3). It is currently not known, however, whether the Fe3+ generated during the 
catalytic cycle (see below) binds as strongly as Fe2+.  
In the catalytic cycle, 2-OG and the target substrate to be hydroxylated first bind within the active 
site, displacing a co-ordinating water molecule. The binding of molecular oxygen to the ferrous iron 
then results in the splitting of the oxygen molecule. One oxygen atom effects oxidative 
decarboxylation of 2-OG to form succinate and CO2, while the other is used in the generation of a 
highly-reactive ferryl-oxo species that acts to hydroxylate the target substrate [121]. In this process, 
Fe3+ is generated at the active site and needs to be reduced back to Fe2+ to maintain the activity of 
the 2-OGDD enzyme. Ascorbate is a necessary co-factor in this process and although the precise 
mechanism is not fully understood, the role of ascorbate in maintaining the function of 2-OGDDs via 
the recycling of Fe3+ to Fe2+ is well established [122].  In the case of the HIF-PHDs, the KM values for 
ascorbate have been determined and were found to be relatively high (Table 3).  Accordingly, their 
activities have been demonstrated to be highly susceptible to physiological cellular fluctuations 
[123].     
The susceptibility of the ferrous iron to oxidation (for example, by superoxide, hydrogen peroxide or 
peroxynitrite, amongst other ROS) might predict the activities of 2-OGDDs to be subject to inhibition 
by some ROS-generating processes. In addition, since ascorbate levels can fluctuate, dependent 
upon the intracellular glutathione:oxidised glutathione redox couple, the cellular redox state itself 
might act as a functional regulator of 2-OGDD activity.    
Again, using the example of the HIF-PHDs, there is good evidence that ROS and/or cellular redox are 
regulators of the activities of 2-OGDD enzymes. However, the source and type of ROS, together with 
the mechanism(s) of inhibition have remained controversial. ROS production necessarily involves 
oxygen, and it is therefore not surprising that different concentrations (and forms) of ROS are 
generated under normoxia, hypoxia and anoxia. Opinion remains divided as to whether ROS levels 
increase or decrease during hypoxia (reviewed in [124]), and this may reflect the different levels of 
hypoxia imposed in the different experimental conditions applied. Thus, the role of ROS in mediating 
the hypoxic response and promoting HIF stabilisation and activity has been difficult to elucidate. 
Evidence for the involvement of both mitochondrial- and NADPH oxidase-derived ROS have been 
reported [125-130], but complete validation of the importance of either (or both) will probably await 
clarification of the precise ROS-dependent mechanism of inhibition of the HIF-PHDs. H2O2 is the ROS 
most commonly demonstrated to be functional in the stabilisation of HIF [131-133]. Thus, 
administration of H2O2 to cells has been shown to be sufficient to stabilise and activate HIF, even 
during normoxia [125, 130]. However, both superoxide and peroxynitrite have also been shown to 
mediate HIF1 stabilisation [134-137]. It should also be noted that (potentially cell-type-specific) 
redox-dependent mechanisms, other than those affecting the activity of PHDs, also impact upon the 
regulation of HIF signalling.  These include the redox-sensitive regulation of transcription [138-140] 
and/or the direct oxidation of reactive cysteine residues of the HIF subunits themselves (for 
excellent reviews, see [141, 142]) While clearly not the focus of this article, these mechanisms need 
to be taken into consideration in the wider context of cellular redox/ROS generation and the 
regulation of HIF-signalling. 
As stated above, the absolute requirement for Fe2+ and its susceptibility to direct oxidation, notably 
by H2O2, might underlie the ROS-dependent regulation of HIF-PHDs and potentially other 2-OGDDs. 
These changes in ROS might themselves be effected or exacerbated by hypoxia and might therefore 
(in the case of the HIF-PHDs) promote the hypoxic activation of HIF, or might act independently.  
Oxidation of Fe2+ might be mediated by the targeted (and potentially highly regulated) generation of 
ROS, for instance by NADPH oxidases and/or mitochondria (reviewed in [143]).  Alternatively, a pro-
oxidant change in the (global) intra-cellular redox state (notably resulting in a reduction in the 
reduced:oxidised glutathione ratio; GSH:GSSG,) might recruit ascorbate as an intracellular free 
radical scavenger, thereby preventing its ability to reduce ferric iron and maintain HIF-PHD activity 
(Figure 5). Consistent with this mechanism of [Fe2+]-dependent HIF-PHD regulation, the transcription 
factor JunD was shown in mouse fibroblasts (3T3 cells) to upregulate antioxidant defence genes to 
prevent the accumulation of H2O2. The genetic ablation of JunD consequently resulted in elevated 
levels of H2O2 and inactivation of PHD2 via oxidation of Fe
2+ within its catalytic domain [132]. There 
are, in addition, other mechanisms which might also be involved in the redox-mediated regulation of 
HIF-PHD activity and some evidence for these has been reported. The modulation of function by 
H2O2-mediated oxidation of susceptible cysteine residues has been well-documented for protein 
tyrosine kinases and phosphatases [144], and is believed to be an important mechanism in many 
redox-mediated signalling pathways. Disulphide bond-mediated homo-dimerization and inactivation 
of PHD-1, -2 and -3 have been observed in cancer cells upon administration of H2O2, and oxidation of 
specific cysteine residues within the catalytic protein domain(s) were implicated in this dimerization 
[145]. However, it remains unclear whether this dimerization can occur under physiological cellular 
conditions.  The redox-mediated initiation of a signal transduction cascade, leading to the post-
translational modification (and inhibition) of HIF-PHDs, is a further potential mechanism that might 
manifest as ROS-dependent regulation of activity. In support of this, the p38 MAPK signalling 
pathway has been shown to mediate mitochondrial-generated, ROS-dependent activation of HIF-1 
under hypoxic conditions [146].  However, it is not clear in this case whether the signalling cascade 
might target the HIF-PHD(s) or HIF1 itself. Finally, it is known that concentrations of both the 
obligatory (2-OG) and inhibitory (succinate and fumarate) metabolites of 2-OGDDs might also be 
altered by free radical production associated with mitochondrial dysfunction [147] and this might 
serve further to mediate the observed ROS-dependent regulation of HIF-PHDs (Figure 5).  
Redox-dependent Regulation of TET Enzymes.  
As in the case of the regulation of TET activity by O2 availability, only a few studies have investigated 
the direct regulation of TET activity by redox mechanisms. Consistent with their requirement for 
Fe2+, ascorbate administration to various cultured cells over the range of 1M-1mM was shown to 
increase the global levels of 5hmC rapidly [148] and this increase was demonstrated to be inhibited 
by siRNAs targeted to (all 3) TETs. In another study, treatment of epithelial cells with 150M H2O2 for 
3 days resulted in a lowered (locus-specific) level of genomic 5hmC and reduced TET activity, 
although the mechanism underlying this inhibition was not determined [149].  
Environmental stresses (such as toxic chemicals, heavy metals, air particles and ozone) are all known 
to induce the production of pro-oxidants [150]. Therefore their effects upon the activities of TETs 
may be significant in pathological epigenetic dysregulation and are beginning to be explored. For 
example, exposure of HEK293 cells to the ROS-generating, benzene metabolite hydroquinone, was 
found to result in a more oxidative cellular redox state which correlated, perhaps surprisingly, with 
increased nuclear TET activity and higher nuclear levels of TET1 protein, with no change in TET1 
mRNA levels [151]. The authors suggest that hydroquinone exposure might induce redox-dependent 
changes in the nuclear import/export mechanisms of TET1. Alternatively, redox-regulated post-
translational modifications affecting TET1 activity and or stability may underlie the observations. 
Redox-active quinones were similarly found to promote the conversion of 5mC to 5hmC, in a TET-
dependent fashion, in a variety of cell lines, including mouse ESCs [152]. In this case, the increases in 
5hmC upon quinone administration were shown to correlate with increased expression (at both 
mRNA and protein level) of the labile, iron-sensitive ferritin light-chain protein which could be 
blocked by chelation of labile iron. The potential regulation of TET activity by modulation of the 
labile iron pool may have particular significance with regard to cancer development and therapy 
[153].  
Very recently, the post translational phosphorylation of TET2 at serine 99, mediated by the 
(potentially redox-regulated) AMPK-signalling pathway [154], was demonstrated to increase TET2 
stability and hence activity [155].  Thus the redox-dependent regulation of TET stability and activity 
by post-translational modifications and other potential mechanisms will likely prove an important 
area of future investigation. An understanding of the source, type and localisation of the ROS signal 
will be important considerations in the experimental design of these investigations.  
Functional Consequences of Redox-modulation of TETs. 
The availability of ascorbate, and its role in the maintenance of the reduced ferrous iron within the 
active sites of TETs, may impact upon many important cellular functions and processes. Cellular 
reprogramming, within the early mammalian embryo and in primordial germ cells, involves phases 
of global DNA demethylation [156, 157] which are likely to be dependent upon the activity of TET 
enzymes. Further, the addition of vitamin C to mouse ESCs cultured in vitro, was shown to promote a 
rapid, global increase in levels of 5hmC, that was completely dependent upon TET1 and TET2 [158], 
highlighting the importance of vitamin C in the maintenance of TET activity and DNA methylation 
fidelity in ESCs. The functional significance of these observations, with respect to a potential role of 
regulated vitamin C levels in developmental-reprogramming in vivo, remain to be investigated.  The 
levels of ascorbate have also been shown to mediate somatic cell reprogramming by acting as a 
switch in the regulation of TET1 function [159]. In a recent study, vitamin C administration was also 
shown to promote the maturation and developmental competence of pig oocytes, concomitant with 
global DNA demethylation, although the requirement for a specific TET was not demonstrated in this 
process [160]. It is also perhaps noteworthy that the levels of expression of the TET enzymes were 
found to be differentially affected in these experiments. Thus TET2 (mRNA and protein) levels were 
significantly increased, while mRNA levels of TET3 were decreased, upon vitamin C administration. 
(The redox-dependent mechanisms underlying the apparent regulation of expression of TET enzymes 
remain to be explored). In another study, administration of ascorbate was demonstrated to inhibit 
the expression and secretion of apo(a) (a liver-expressed glycoprotein found in plasma and a risk 
factor for coronary heart disease) in HepG2 cells, via promoting TET2-dependent DNA demethylation 
[161].  
A potential functional consequence of the redox-dependent regulation of TET activity is also 
suggested by the association of traffic-related air pollution, (which is well known to promote 
oxidative cellular damage [162]), with altered (increased) levels of global 5hmC levels, found in the 
airway epithelial cells of asthma sufferers [163]. In addition, the redox-dependent up-regulation of 
TET1 expression and function has been reported to underlie the acquisition of resistance to the 
anticancer agent, 5-fluorouracil [164]. 
Regulation of JmjCs by Redox Mechanisms 
As in the case of the TETs, ascorbate has been shown to be an essential cofactor in the maintenance 
of the activities of the JmjC histone demethylases, evidencing their requirement for Fe2+  (reviewed 
in [165]). In one study, an increase in several histone methylation marks, including H3K4me3, was 
exhibited after human bronchial epithelial cells (BAEC-2Bs) were exposed to H2O2 for 3 hours, while 
pre-incubation with ascorbate prevented these changes [149].  This suggests that the direct of 
oxidation of Fe2+ by H2O2, which is reversible by ascorbate, was the cause of the inhibition in this 
case. There have also been several studies investigating the potential inhibition of the histone 
demethylases by metal ions which can compete with Fe(II) for the active site and/or induce oxidative 
stress.  Nickel exposure has been shown to increase global levels of H3K4me3, H3K9me2 and 
H3K9me1 in several studies [166, 167]. Mechanistically, this is probably due to the displacement of 
the Fe(II) by nickel, which has an approximately 3-times greater affinity for the JmjC active site than 
iron itself (reviewed in [168]). Moreover, in a number of cell-based studies, both arsenic and 
chromium exposure have been shown to result in altered patterns of histone methylation, 
potentially  mediated by dysregulated JmjC activity [167, 169-171]. Arsenic and chromium are both 
potent generators of oxidative stress within cells, but the precise mechanisms whereby they might 
inhibit 2-OGDDs is not clear [168].  Intriguingly, in one study the dysregulation of histone 
methylation by chromium was shown to be (in part) ablated by ascorbate, suggesting that chromium 
might be acting to deplete the reduced intracellular levels of ascorbate [170].  
As noted above, there is evidence for the redox-dependent regulation of HIF-PHDs by cysteine-thiol 
oxidation, leading to disulphide bond formation and protein inactivation [145]. As yet, this 
mechanism has not been demonstrated to be functionally relevant with respect to either JmjCs or 
TETs.  However, such a mechanism has been suggested to switch the activity of a member of the LSD 
histone demethylase; KDM1A [172]. Indeed, the involvement of redox-mechanisms are increasingly 
being demonstrated and/or suggested to underlie regulation of many epigenetic-modifying 
processes, in addition to the demethylation of DNA and histones [173]. 
Functional Consequences of Redox Regulation of JmjCs 
As is the case for the TET enzymes, the JmjC histone demethylases appear to play important roles in 
cellular programming and reprogramming. The reprogramming of somatic cells into induced 
pluripotent stem cells (iPSCs) is known to be greatly accelerated and enhanced by ascorbate. It has 
also been demonstrated that this is dependent upon induction of H3K36me2/3 demethylation, 
catalysed by KDM2A and KDM2B (JHDM1A and JHDM1B) [174].  Intriguingly, in that study it was also 
noted that KDM2B co-operates with Oct4 (perhaps through a physical interaction) to induce 
expression of microRNA cluster 302/367, which is an integral component of the pluripotent 
phenotype. In another study, ascorbic acid was demonstrated to promote the maturation of porcine 
oocytes, concomitant with the erasure of the (repressive) histone methylation mark, H3K27me3. The 
levels of other histone methylation marks assessed in this study either did not change (H3K9me3), or 
were shown to increase (H3K4me3 and H3K36me3). Intriguingly, the mRNA expression of KMD5B 
(which acts to remove the activating H3K4me3 mark) was decreased by ascorbate administration, 
perhaps consistent with the increase in H3K4me3 levels. The potential mechanisms underlying this 
ascorbate- (redox)-mediated regulation of transcription of the JmjC(s) remain to be investigated. 
Given the clear association between epigenetic dysregulation in cancers and the capability of 
ascorbate to regulate JmjCs (and TETs), it would seem highly important to understand such 
mechanisms fully, in order to exploit the therapeutic possibilities of ascorbate.  
The dysregulation of the JmjCs by exposure to toxic metals, such as nickel, arsenic and chromium, 
probably accounts in part for their toxicity.  For example, exposure to these elements has been 
implicated in the occurrence of numerous human cancers and in many cases this has been attributed 
to their abilities to alter chromatin structure (reviewed in [168]). A full understanding of the redox-
based mechanisms that underlie the dysregulation of these epigenetic modifiers, in response to such 
environmental stresses, could have major beneficial future therapeutic implications.  
Regulation of RNA Function by Methylation. 
Although less studied, it is clear that the function of RNA is also subject to regulation by covalent 
methylation, predominantly at N6-methyladenosine (m6A) (reviewed in [175]). Further, the discovery 
of enzymatic systems capable of both adding and removing m6A has led to the proposal that they 
too may be subject to dynamic regulation by epigenetic mechanisms (termed “RNA epigenetics” 
(reviewed in [176]).  Intriguingly, the demethylating enzymatic systems have again proven to be 
members of the 2-OGDD family, which, as in the case of the TETs, act to remove methyl groups by 
successive oxidative reactions [176, 177]. Fat mass and obesity-associated protein (FTO) was the first 
RNA demethylase to be identified [178].  It preferentially acts upon single-stranded RNA or DNA to 
demethylate m6A, and has been shown to be nuclear-localised. This observation, together with the 
very low levels of m6A on genomic DNA within (most) mammalian cells and tissues, suggest that its 
main target substrate is nuclear RNA (including mRNA, lucRNA and potentially other RNA species).  
Little is known of the functional consequences of FTO-mediated RNA demethylation. However, 
genetic ablation of FTO in mice was shown to increase post-natal lethality and growth retardation 
[179], while the levels of FTO expression are regulated by feeding and fasting, consistent with an 
association with obesity [180].  
ALKBH5 is another mammalian demethylase, shown to be a member of the 2-OGDD superfamily, 
which acts to reverse m6A by oxidation in mRNA both in vitro and in vivo [181]. As for FTO, ALKBH5 
has also been shown to co-localize with nuclear speckles and to show efficient demethylation 
activity towards various nuclear RNA species, including mRNA [181]. Silencing of ALKBH5 in human 
cell lines acted to both increase total m6A levels on polyadenylated RNA and significantly affected 
mRNA nuclear export and processing [181].  In mice, ALKBH5 has been shown to display the highest 
expression levels in testes. Intriguingly, ALKBH5-deficient male mice were characterised by impaired 
fertility, resulting from apoptosis of meiotic metaphase-stage spermatocytes [181]. Clearly, as 
members of the Fe(II)-dependent 2-OGDD superfamily, both of these RNA demethylases may be 
subject to regulation by both O2 availability and redox-dependent mechanisms. This is a completely 
unexplored area of investigation which will, no doubt, be the subject of future investigations.  
Conclusions 
The finding that epigenetic erasers, which act to remove methyl groups from DNA and protein, are 
members of the 2-OGDD superfamily has clear implications with respect to dynamic regulatory 
mechanisms which might modulate their functions. The capacity for the activities of the TET and 
JmjC proteins to be regulated by metabolites, oxygen availability and redox-based mechanisms are 
likely critical in their proven functions in cellular fate determination during development. It might 
also underlie their dysregulation in pathologies associated with distortions of metabolic flux, hypoxia 
and oxidative stress, such as tumorigenesis. The wider clinical consequences of such regulation are 
also clear. In addition to cancer, many other pathological conditions, ranging from heart failure to 
stroke, can result in lasting oxygen shortage associated with worsening morbidity and mortality. The 
impaired activity of the epigenetic modifiers in these clinical settings suggest a clear potential 
mechanism whereby an increasingly hypoxic environment might lead to altered gene expression, 
contributing to disease progression.  
Definitive evidence for physiological [O2]-dependent modulation of activity of both TETs and JmjCs is 
now growing.  Further, the members of both families of enzymes have, in some studies, 
demonstrated differential dependencies upon O2 availability. This clearly might facilitate a great 
range of cellular responses to a given environmental cue, dependent upon the expression patterns 
of the enzymes in any given cell type.  Similarly, there is increasing evidence for redox regulation of 
these enzymes, although the precise mechanisms remain to be determined. However, it is clear that 
the relationships between both hypoxia/cellular redox and TET/JmjC activity are complex.  For 
example, reductions in specific activity due to lower available O2 and/or increased ROS, can, in some 
instances, be countered by induced gene expression, often making elucidation of the underlying 
mechanisms challenging.  
The roles of TETs and JmjCs in (dynamic) cellular homeostatic processes have not been extensively 
studied.  However, TET2 specifically has been implicated as both a master regulator of smooth 
muscle cell plasticity [182] and as a controller of cardiomyocyte gene expression during the 
hypertrophic response [183]. JmjCs have similarly been implicated in cardiac hypertrophy [184] and 
also in the maintenance of cellular redox homeostasis [185].  The potential roles of these proteins in 
other homeostatic mechanisms in which O2 and/or cellular redox are important regulatory cues 
(such as angiogenesis and erythropoiesis), remain to be explored. 
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Table 1.  Expression profiles, and (patho)- physiological functions of TET proteins 
 
            TET 
Protein 
Expression as 
described in the 
Human Protein Atlas 
[186, 187] 
 
Functions (biological 
and catalytic) 
 
Associations with 
Disease 
 
TET 1  
(Methylcytosine 
dioxygenase 1) 
 
RNA expression in cerebral 
cortex (neuronal, glial and 
endothelial cells), thyroid and 
parathyroid glands (glandular 
and endothelial cells), smooth 
muscle cells, gallbladder, male 
and female reproductive tracts 
Active DNA demethylation by 
catalytic conversion of 5-
methylcytosine (5mC) into 5-
hydroxymethylcytosine (5hmC) 
[33]  
 
Chromatin regulation by O-linked 
N-acetylglucosamine transferase 
recruitment to transcriptional 
start sites promoting histone 
H2B GlcNAcylation [188] 
 
 
Involved in trophoblast stem cell 
maintenance and integrity, and 
cell-cycle progression[189] 
 
 
Transcriptional regulation via 
interaction with the 
transcriptional corepressor, 
SIN3A [190]  
 
Upregulated in inflammatory 
microenvironment of 
hyperinsulinemia and 
invasive ductal carcinoma 
[191].    
 
Plays an essential oncogenic 
role in  MLL-rearranged 
leukaemia [192] 
 
Downregulated in gastric and 
prostate cancer and 
numerous solid cancers 
(breast, melanoma, glioma, 
colon and liver) along with 
other TET family members 
[96, 193-196]. 
 
TET 2  
(Methylcytosine 
dioxygenase 2) 
 
RNA and protein expressed in 
cerebral cortex, myocytes, 
smooth muscle cells, cells of 
the immune system (bone 
marrow, appendix, tonsils, 
spleen), thyroid, parathyroid 
and adrenal gland, 
hepatocytes and bile duct 
cells, islet of Langerhans and 
exocrine glandular cells of 
pancreas, the gastrointestinal 
tract, adipocytes, male and 
female reproductive organs 
and skin. 
 
Shared demethylation and 
chromatin regulation role with 
other TET family members [36, 
37, 48, 190]  
 
Regulates hematopoietic stem 
cell (HSC) self-renewal, 
haematopoiesis and myeloid 
lineage commitment and 
differentiation.[197] 
 
TET2 is targeted by microRNA-
22 to regulate HSC self-renewal 
and transformation [198] 
 
Involved in trophoblast stem cell 
maintenance and integrity [189] 
 
 
Somatic TET2 mutations 
altering the enzymes catalytic 
activity observed in many 
cancers (myelodysplasia, 
AML, breast, lung, pancreas 
and liver [52, 196, 199-201])  
 
4q24 (Tet2) is a common 
chromosomal deletion 
observed in hematopoietic 
malignancies. [202] 
 
TET2 mutations are 
frequently observed in 
chronic myelomonocytic 
leukaemia patients and are 
used as a prognostic 
biomarker for the disease 
[203] 
 
TET 3 
(Methylcytosine 
dioxygenase 3) 
 
Expression profile similar to 
TET2 at RNA and protein level 
 
Shared demethylation and 
chromatin regulation role with 
other TET family members [36, 
37, 48, 190] 
  
Involved in developmental 
regulation via chromatin 
reprograming in zygote following 
fertilization, as well as 
transcriptional regulation of early 
development genes [204] 
 
Responsible for global erasure 
of DNA methylation patterns in 
the paternal pronucleus in 
zygotes [205].  
 
Stabilizes thyroid hormone T3 
nuclear receptors by promoting 
their association to chromatin 
[206]. 
Negative regulator of IFNβ in 
response to viral 
infection.[207] 
  
Loss of function results in 
increased aggressive myeloid 
cancer in mice [208] 
 
Regulates the balance between 
neural and mesoderm cell fate 
determination [66]. 
   
 
 
 
 
 
Table 2.  Functions of JmjC histone demethylases  
JmjC  Alternative 
names 
Functional 
Domains  
Histone 
substrate 
Function Role in Disease 
KDM2A JHDM1A/ 
FBXL11, 
FBL11/FBL7/ 
CXXC8 
JmjC; CXXC; 
PHD; FBox;LRR 
H3K6me1/2 Regulator of NF-KB 
pathway [209]. 
Integration of histone 
and DNA modifications 
via interactions with 
HP1. [210] 
Oncogene in breast cancer. 
Promotes DNA methylation 
through TET2  inhibition 
[211] 
KDM2B JHDM1B/FBXL10
/PCCX2/ CXXC2 
JmjC; CXXC; 
PHD; FBox; 
LRR 
H3K6me1/2; 
H3K4me3 
Regulates somatic 
reprogramming 
through interaction 
with Polycomb 
complexes [212]. 
Regulator of apoptotic 
pathway [213] 
Drives pancreatic cancer 
tumorigenicity through 
Polycomb interaction [214] 
Promotes breast cancer 
proliferation [215] 
KDM3A JHDM2A/JMJD1/
JMJD1A/ TSGA 
JmjC H3K9me1/2 Direct target of HIF 
and upregulated in 
hypoxia [100]. Involved 
in cell cycle 
control[216] 
Transcriptional regulation of 
androgen receptors in 
prostate cancer [217]. 
Regulates ovarian 
stemness cancer 
chemoresistance [218]. 
Promotes cancer 
progression via HOXA1 
gene regulation [216] 
KDM3B JMJD1B/NET22/5
qNCA 
JmjC H3K9me1 Tumor-suppressive 
activity [219] 
Regulates somatic 
growth and female 
reproductive function 
[220] 
Tumour–promoting activity 
[219]. Promotes colorectal 
cancer progression [221] 
Promotes leukemogenesis 
[222] 
 
KDM4A JMJD1C/TRIP8/J
HDM2C 
JmjN; JmjC; 
PHD; Tudor 
H3K9me2/3; 
H3K36me2/3 
Regulates HIF-1 levels 
via the H3K9me3 mark 
[223] 
Deregulated in prostate, 
bladder, colorectal, lung 
and breast cancer [224]. 
Regulates tumour 
metabolism through 
interaction with E2F1 [225] 
KDM4B JMJD2B/TDRD14
B 
JmjN; JmjC; 
PHD; Tudor 
H3K9me2/3; 
H3K36me2/3 
Direct target of HIF 
and upregulated in 
hypoxia [100]  
Serves as a DNA 
Damage Response 
protein [226] 
Regulates estrogen 
receptor signalling cascade 
in breast cancer [227]. 
Regulates peritoneal 
seeding of cancer cells 
[228] 
KDM4C TDRD14C/JHDM
3C/JMJD2C 
JmjN; JmjC; 
PHD; Tudor 
H3K9me2/3; 
H3K36me2/3 
Direct target of HIF 
and upregulated in 
hypoxia [100] 
Involved in cell proliferation 
and chromosome 
segregation in breast 
cancer [229]. In colon 
cancer mediates Wnt/Notch 
pathway cross talk to 
regulate sphere formation 
in colon cancer [230] 
KDM4D JMJD2D/JHDM3
D 
JmjN; JmjC H3K9me2/3; 
H3K36me2/3 
Regulates DNA 
replication by 
facilitating pre-initiative 
complex formation 
[231]. Plays a role in 
DNA damage 
response [232] 
Upregulated in pancreatic 
adenocarcinoma [233] 
KDM4E KDM4DL/JMJD2
D 
JmjN; JmjC (H3K4me2/3 Putative pseudogene, 
but activity shown to 
regulated by O2 
availability in vitro 
[104]  
 
KDM5A RBP2/JARID1A/R
BBP2 
JmjN; ARID; 
JmjC; PHD; 
C5HC2-ZF 
H3K4me2/3 Involved in 
maintenance of 3’UTR 
length through 
DICER1 [234].  
Implicated in renal, ovarian, 
liver and acute 
lymphoblastic leukemia 
(ALL). [235-238]   
KDM5B JARID1B/PUT1/P
LU-1/CT31 
JmjN; ARID; 
JmjC; PHD; 
C5HC2-ZF 
H3K4me2/3 Direct target of HIF 
and upregulated in 
hypoxia [100] 
Involved in 
maintenance of 3’UTR 
length through 
DICER1 [234]. 
Plays a role in melanoma 
development and 
progression [239].  
Implicated in oral cancer 
and glioma [240, 241].  
KDM5C JAIRD1C/SMCX/
XE169/ 
DXS1272E/MRX1
3 
JmjN; ARID; 
JmjC; PHD; 
C5HC2-ZF 
H3K4me2/3 Direct target of HIF 
and upregulated in 
hypoxia [100] 
Plays a role in gastric 
cancer cell proliferation 
[242].  Overexpressed in 
breast cancer [243]  
KDM5D JARID1D/SMCY/
HYA 
JmjN; ARID; 
JmjC; PHD; 
C5HC2-ZF 
H3K4me2/3 Evidence for a role in 
immune recognition 
[244] 
Strong evidence for a role 
in prostate cancer [245] 
KDM6A UTX/ 
BA386N14.2 
TPR; JmjC;  H3K27me2/3 Regulates endoderm 
differentiation through 
WNT signalling 
pathway [246] 
Mutated in bladder cancer 
[247]. Mutations associated 
with Kabuki syndrome [248] 
KDM6B  JMJD3 
 
JmjC;  H3K27me2/3 Regulates endoderm 
differentiation through 
WNT signalling 
pathway [246] 
Involved in 
differentiation of 
germinal centre B-cells 
[249] 
Mediate multiple myeloma 
cell growth and survival 
[250]. Promotes survival of 
diffuse large B-cell 
lymphoma subtypes [249] 
KDM7A JHDM1D JmjC;PHD H3K27me1/2; 
H3K9me1/2;  
Implicated in neural 
differentiation [251] 
Modulates endothelial 
inflammatory response 
[252] 
Acts as a tumour growth 
suppressor role via 
downregulation of 
angiogenesis [253].  
KDM7B PHF8/JHDM1F/Z
NF422 
JmjC;PHD H3K9me1/2; 
H4K20me1 
Regulates transcription 
of rRNAs  [254, 255] 
Promotes ALL, breast, lung 
and prostate cancer. [256-
259]   
KDM7C PHF2/CENP-
35/JHDM1E 
JmjC;PHD H3K9me2 Regulates transcription 
of  rRNAs [254]  
Mutations associate with 
gastric and colorectal 
cancer [260]  
Downregulated in ALL  
[261] 
Tumour suppressor role in 
cancer development in 
association with p53 [262] 
KDM8 JMJD5ROX/MDI
G 
JmjC H3K36me2 Involved in a control of 
cell cycle and 
proliferation [263] 
Implicated as a potential 
oncogene in colon cancer 
[264] 
MINA MDIG/RIOX2 JmjC H3K9me3 Implicated in DNA 
double strand break 
repair [265] 
Contributes to 
pathogenesis of cancer by 
affecting cell growth and 
motility [266]. Prognostic 
marker of pancreatic 
cancer [267] Controls 
proliferation and invasion of 
non-small cell lung cancer 
and glioblastoma[268, 269]  
NO66 MAPJD/ROX JmjC H3K4me1/3; 
H3K36me2 
Potential role in 
ribosome biogenesis 
[270]  Possible role in 
regulation of 
osteoblast-specific 
transcription  [271] 
Prognostic biomarker for 
colorectal cancer [272]  
Upregulated in renal cell 
tumours [273] 
 
 
Domain Key : ARID – AT rich interacting domain; PHD- Plant Homeodomain; FBOX- FBox 
domain; CW- CW type zinc finger domain; TUDOR- Tudor domain; JmjC- Jumonji C domain; 
JmjN- Jumonji N domain; CXXC- CXXC zinc finger domain; TPR – tetratricopeptide domain 
 
 
 
 
 
  
Table 3. KM values for selected 2-OGDDs for O2, 2-oxoglutarate, Fe
2+ and ascorbic acid 
Enzyme  
 
Km 
app(O2)/µM 
 
Km 
app(2-OG )/µM 
 
Km 
app(Fe2+)/µM 
 
Km 
app 
(Ascorbic Acid)/µM 
 
HIF-PHD1 
 
230 [69]  
 
2 ± 0.4 [274] 
 
0.03 [122] 
 
 170 [70] 
 
HIF-PHD2 
 
∼250 μM to 1.7 mM  
[69, 275-277] 
1 ± 0.2  [274] 0.03 [122] 180 [70] 
HIF-PHD3 
 
230 [69] 12 ± 4  [274] 0.1 [122] 140 [70] 
FIH 
 
90-200 [278] 
90 [70] 
 
110 ± 20 μM [278]  
25 ± 3 [70] 
 
0.5 ± 0.2  [70] 
 
260 ± 50 [70] 
 
KDM4A 1-359 
 
173 +23   [105] 
57 ± 10 [279] 
 
23 [280] 
10-37 [279] 
 
Not determined 
  
Not determined 
KDM4C 158 ± 13  [279]  
 
17.1 ± 0.9 [281] 
10-37 [279] 
1.3 ± 0.4 µM [281] Not determined 
KDM4E 197 ± 16 [279]  
 
10-37 [279] Not determined Not determined 
TET1 1367–2039 ~30  [68]              55 [280] 5 [280] Not determined 
TET2 916–1921 
 
~30   [68]            60 [280]  4 [280] Not determined 
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Legends to figures 
Figure 1. DNA and histone demethylation pathways. A. Removal of all modified bases can be passive, 
via DNA replication. Active demethylation involves the successive oxidative conversion of 5-
methylcytosine (5mC) to 5-hydroxymethylcytosine (5 hmC), 5-formylcytosine (5fC) and 5-
carboxylcytosine (5caC) by TET proteins. These marks can subsequently be lost upon replication, or 
can be converted to unmodified cytosine via the action of Thymine DNA Glycosylase (TDG) and base 
excision repair (BER) pathway. SAM; S-adenosyl methionine, DNMT; DNA methyltransferase. B. JmjC-
mediated hydroxylation of mono-, di- and tri-methyl-lysine.  The oxidative decarboxylation of α-
ketoglutarate forms CO2, succinate, and a reactive iron (IV)- oxo intermediate which then leads to 
further lysine hydroxylation to yield hemiaminal. This hemiaminal due to its unstable nature is 
further fragmented to release formaldehyde and non-methylated lysine residue. 
 
Figure 2.  
Schematic depicting the chromosomal locations, gene structures and best-characterised protein 
isoforms of the human TET proteins. All contain the C-terminal catalytic domain comprising the 
double-stranded β-helix domain (DSBH) with Fe(II) and 2-OG binding sites and an adjacent  Cys-rich 
region. Additionally, TET1 and TET3 have a DNA binding, CXXC domain made up of two Cys4-type 
zinc finger motifs at their N-termini. The start of translation is indicated (arrowed ATG).  Coding exon 
sequences are shaded.   
 
Figure 3. 
Schematic depicting  how the  differential activities of the TET proteins (which we have observed in 
HEK 293 cells, over a gradient of 0.5 to 5% O2) might combine, in the early embryo to generate 
specific regions of low (back slashed box), intermediate (forward slashed box) or high (speckled box) 
levels of 5hmC.  These differential levels of 5hmC might then act to facilitate spatial-specific patterns 
of gene expression, leading to distinct differentiation programmes. TET1 activity increases 
asymptotically, TET 2 activity remains unchanged and TET3 activity exhibits a bell-shaped curve over 
this graded range of oxygen.  
Figure 4. 
Schematic of the association of available oxygen concentration and TET function. A reduction in the 
O2 substrate can result in reduced TET catalytic activity. In opposition to this, the expression of TETs 
can be induced under more hypoxic conditions by HIF. Increased expression of TETs can then result 
in increased 5hmC which can interact with, and promote the binding of HIF to HIF-regulated 
promoters. Finally, hypoxia-induced, increased expression of TET1/TET3 has been shown to result in 
the direct interaction with the TNF promoter to induce expression and downstream p38-MAPK 
signalling. CS; catalytic site. 
Figure 5. 
Suggested mechanisms by which altered redox state or the production of pro-oxidants might reduce 
the activity of 2-oxoglutarate dioxygenases. Oxidation of the ferrous iron due to the intracellular 
production of H2O2, or due to lowered levels of (reduced) ascorbate resulting from cellular oxidative 
stress could inactivate the catalytic site (CS) of the enzyme. Cysteine thiol (SH) oxidation by H2O2 
could result in protein dimerization and inactivation. H2O2-mediated inactivation of a protein 
tyrosine phosphatase (PTP) resulting in activation of a protein tyrosine kinase (PTK) and post-
translational modification (phosphorylation (P) of a tyrosine (Tyr) residue) could inactivate the 
enzyme. Finally, the concentrations of the obligatory 2-oxoglutarate (2-OG) might increase, and 
levels of the inhibitory metabolites; succinate (Suc) and fumarate (Fum), might decrease, as a result 
of free radical production associated with  mitochondrial dysfunction. GSH; reduced glutathione, 
GSSG; oxidised glutathione. 
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Highlights 
 Gene transcription is regulated in part by epigenetic erasers which act to remove methyl 
groups from DNA and histones, termed TET and JmjC proteins, respectively 
 Both TETs and JmjCs belong to a superfamily of proteins which are 2-oxoglutarate- and 
Fe(II)-dependent dioxygenases 
 Consequently the activities of these enzymes are regulated in part by cellular redox and O2 
availability 
 TETs and JmjCs can therefore facilitate the transduction of dynamic changes in cellular redox 
and O2 concentration with changes in gene expression  
 
 
 
 
